Gene therapy Market Emerging Trend, Opportunities, Key Players, Huge Growth, Revenue Analysis, 2024-2035 The global gene therapy market is growing rapidly; it is estimated to be worth USD 2.4 billion in 2024 and is anticipated to reach USD 16.5 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 19.25% during the forecast period. The growth of the gene therapy market is mainly attributed to the increasing demand for tailored therapies to treat diseases that occur due to genetic defects. Gene therapy is an advanced technique that enables the replacement of disease-causing genes with normal functional genes. This treatment regimen has been implemented for the correction of mutated genes in patients by utilizing molecular carriers such as viral and non-viral vectors. Owing to its therapeutic efficacy in treating the disease at the cellular level, several industrial stakeholders have increased their research and development activities for the development of next-generation gene therapies. It is worth noting here that in August 2017, Tisagenlecleucel was the first gene therapy to receive approval from the FDA to treat relapsed or refractory pediatric and young-adult B-cell acute lymphoblastic leukemia. In 2020, Libmeldy™ (an ex vivo gene therapy) received approval from the FDA to treat metachromatic leukodystrophy. At present, more than 200 gene therapies are currently being evaluated under phase II and phase III clinical studies. The ongoing advancements in gene editing tools to develop gene-based therapies and increasing research activities in the field are anticipated to drive growth during the forecast period. You Can View the Complete Report on the Gene Therapy Market Online by Clicking On the Given Link https://www.rootsanalysis.com/reports/gene-therapies-market/268.html